IL1B and uveitis: The IL‐1β receptor antagonist anakinra (ANA), anti‐IL‐1β antibody canakinumab (CAN), and recombinant humanized anti‐IL‐1β antibody gevokizumab (XOMA 052) have good clinical results in ocular diseases such as uveitis secondary to Behçet's disease (BD; Gul et al,2012; Ugurlu et al,2012; Vitale et al,2014; Cantarini et al,2015; Emmi et al,2016).